BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting BASEL, Switzerland…